NCT02238145已完成不适用
Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law] of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 660
- 主要终点
- Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile
研究概览
简要总结
To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primarily patients of both gender, older than 30 years,who suffer from chronic obstructive airways disease
- •Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
排除标准
- •Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhaletten®
研究组 & 干预措施
Chronic Obstructive Airways Disease
干预措施: Atrovent® Inhaletten (Drug)
结局指标
主要结局
Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile
时间窗: Up to 4 weeks after first study drug administration
次要结局
- Investigator assessment of tolerability on a 4-point scale(Up to 4 weeks after first study drug administration)
- Investigator assessment of efficacy on a 4-point scale(Up to 4 weeks after first study drug administration)
- Number of patients with adverse drug reactions(Up to 4 weeks after first study drug administration)
- Number of patients who withdrew from the study(Up to 4 weeks after first study drug administration)
- Number of patients who changed the concomitant medication(Up to 4 weeks after first study drug administration)
- Number of patients who continued treatment(Up to 4 weeks after first study drug administration)
- Patient assessment of tolerability on a 4-point scale(Up to 4 weeks after first study drug administration)
- Patient assessment of efficacy on a 4-point scale(Up to 4 weeks after first study drug administration)
研究者
相似试验
已完成
不适用
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02238171Boehringer Ingelheim346
已完成
不适用
Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02233894Boehringer Ingelheim526
已完成
不适用
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02233881Boehringer Ingelheim4,222
已完成
不适用
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02238197Boehringer Ingelheim477
已完成
不适用
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways DiseasePulmonary Disease, Chronic ObstructiveNCT02238132Boehringer Ingelheim374